1563 related articles for article (PubMed ID: 18759144)
1. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.
Søndergaard J; Høyer M; Petersen JB; Wright P; Grau C; Muren LP
Acta Oncol; 2009; 48(2):238-44. PubMed ID: 18759144
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
[TBL] [Abstract][Full Text] [Related]
3. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
4. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
[TBL] [Abstract][Full Text] [Related]
5. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences.
Muren LP; Wasbø E; Helle SI; Hysing LB; Karlsdottir A; Odland OH; Valen H; Ekerold R; Johannessen DC
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1034-41. PubMed ID: 18249502
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of IMRT to cover pelvic nodes while escalating the dose to the prostate gland: dosimetric data on 35 consecutive patients.
Bayouth JE; Pena J; Culp L; Brack C; Sanguineti G
Med Dosim; 2008; 33(3):180-90. PubMed ID: 18674682
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
8. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.
Mell LK; Tiryaki H; Ahn KH; Mundt AJ; Roeske JC; Aydogan B
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1504-10. PubMed ID: 18640499
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies.
Georg P; Georg D; Hillbrand M; Kirisits C; Pötter R
Radiother Oncol; 2006 Jul; 80(1):19-26. PubMed ID: 16766068
[TBL] [Abstract][Full Text] [Related]
11. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique.
Ganswindt U; Paulsen F; Corvin S; Hundt I; Alber M; Frey B; Stenzl A; Bares R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):347-55. PubMed ID: 17236960
[TBL] [Abstract][Full Text] [Related]
12. A concomitant tumour boost in bladder irradiation: patient suitability and the potential of intensity-modulated radiotherapy.
Muren LP; Redpath AT; McLaren D; Rørvik J; Halvorsen OJ; Høstmark J; Bakke A; Thwaites D; Dahl O
Radiother Oncol; 2006 Jul; 80(1):98-105. PubMed ID: 16876274
[TBL] [Abstract][Full Text] [Related]
13. Influence of organ motion on conformal vs. intensity-modulated pelvic radiotherapy for prostate cancer.
Hysing LB; Skorpen TN; Alber M; Fjellsbø LB; Helle SI; Muren LP
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1496-503. PubMed ID: 18538493
[TBL] [Abstract][Full Text] [Related]
14. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?
Sanguineti G; Cavey ML; Endres EJ; Brandon GG; Bayouth JE
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):151-60. PubMed ID: 16198066
[TBL] [Abstract][Full Text] [Related]
15. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer.
Al-Mamgani A; Heemsbergen WD; Peeters ST; Lebesque JV
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):685-91. PubMed ID: 18718725
[TBL] [Abstract][Full Text] [Related]
16. Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression.
van de Bunt L; van der Heide UA; Ketelaars M; de Kort GA; Jürgenliemk-Schulz IM
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):189-96. PubMed ID: 15978745
[TBL] [Abstract][Full Text] [Related]
17. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations.
Guerrero M; Li XA; Ma L; Linder J; Deyoung C; Erickson B
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):933-9. PubMed ID: 15936580
[TBL] [Abstract][Full Text] [Related]
19. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
20. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
Teh BS; Dong L; McGary JE; Mai WY; Grant W; Butler EB
Med Dosim; 2005; 30(1):25-30. PubMed ID: 15749008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]